Arch Biopartners Inc.
Arch Biopartners Inc is a portfolio based biotechnology company. It focuses on the development of innovative technologies. The company's portfolio of technology includes AB569 which is a new drug candidate for treating antibiotic-resistant bacterial infections, primarily in the lungs and urinary tract; MetaBlok which is a new drug candidate targeting sepsis, cancer metastasis and inflammation based diseases; Arch Inflammation which is a novel treatment for chronic kidney and bowel diseases caused by non-infectious inflammation. It also develops Borg technology which is a solid surface interface to solid metal and plastic surfaces to inhibit biofilm formation and reduce corrosion; and MetaMx which is a synthetic molecule that targets brain tumor-initiating cells and invasive glioma cells.